Erythrocytosis Is Rare With Exogenous Testosterone in Gender-Affirming Hormone Therapy
The Journal of Clinical Endocrinology & Metabolism · 19.04.2024 · 109 (5) · 1285-1290
DOI: 10.1210/clinem/dgad651 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 27.11.2023. Verfasst von Nithya Krishnamurthy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA. Hauptthemen laut MEDLINE: Polycythemia, Transgender Persons. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Context
Studies have found a variable incidence of erythrocytosis among people using testosterone as part of gender-affirming hormone therapy (GAHT).
Objective
To examine the effect of using exogenous testosterone as GAHT on hematocrit in a large North American cohort.
Methods
We conducted a cross-sectional analysis of testosterone and hematocrit laboratory values in 6670 patients who were prescribed testosterone through Plume, a national provider of GAHT. The prevalence of erythrocytosis, the mean hematocrit at predetermined testosterone thresholds and with varying routes of testosterone administration were assessed.
Results
Among 6670 individuals, 560 (8.4%) had a hematocrit ≥50%, 182 ≥ 52% (2.7%), and 60 ≥ 54% (0.9%). There was significant variation (P < .001) in hematocrit between different clinically relevant testosterone thresholds (T < 50 vs T 50-299 vs T 300-999 vs T ≥ 1000 ng/dL) and when comparing serum testosterone in increments of 50 ng/dL within the target range for males (300-1000 ng/dL) (P < .001). Mean hematocrit ranged from 41.84% (T < 50 ng/dL) to 45.68% (T 900-949 ng/dL). Patients on intramuscular testosterone had a higher mean hematocrit than those on transdermal testosterone (44.96% vs 43.41%, P < .001). Both route of administration (P < .001) and testosterone level (P < .001) had statistically significant associations with hematocrit when controlling for each other.
Conclusion
While the magnitude of change in hematocrit with serum level and route of administration of testosterone was statistically significant, the absolute levels were within the normal range, unlikely to be clinically meaningful. These findings, along with the low prevalence of erythrocytosis, should help allay concerns about the use of testosterone as GAHT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
- Division of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
- Clinical Research Division, Plume Health, Denver, CO 80209, USA.
- Center for Transgender Medicine and Surgery, Mount Sinai Health System, New York, NY 10029-6574, USA.
ORCID-Profile: Nithya Krishnamurthy
Zitieren
APA
Krishnamurthy, N., Slack, D. J., Kyweluk, M., Cullen, O., Kirkley, J., & Safer, J. D. (2024). Erythrocytosis Is Rare With Exogenous Testosterone in Gender-Affirming Hormone Therapy. The Journal of Clinical Endocrinology & Metabolism, 109(5), 1285-1290. https://doi.org/10.1210/clinem/dgad651
Vancouver
Krishnamurthy N, Slack DJ, Kyweluk M, Cullen O, Kirkley J, Safer JD. Erythrocytosis Is Rare With Exogenous Testosterone in Gender-Affirming Hormone Therapy. The Journal of Clinical Endocrinology & Metabolism. 2024;109(5):1285-1290. doi:10.1210/clinem/dgad651
BibTeX
@article{Krishnamurthy2024,
author = {Krishnamurthy, Nithya and Slack, Daniel J and Kyweluk, Moira and Cullen, Olivia and Kirkley, Jerrica and Safer, Joshua D},
title = {Erythrocytosis Is Rare With Exogenous Testosterone in Gender-Affirming Hormone Therapy},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {109},
number = {5},
pages = {1285--1290},
doi = {10.1210/clinem/dgad651}
}
EUVIMED